Cerus Corporation · NASDAQ:CERS

Cerus — Investor Presentation (December 2025)

28 slides from Cerus's investor presentation, December 2025

  1. Slide 1: Cerus Corporation

    Cerus Corporation December 2025 Not to be Reproduced

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Except for the historical statements contained herein, this presentation contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: Cerus’ 2025 annual product revenue guidance and key milestones for 202

  3. Slide 3: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures This presentation includes certain financial information presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including adjusted EBITDA and the percentage growth in EMEA product revenue, excluding the impac

  4. Slide 4: Cerus: Focused on Safeguarding the Blood Supply

    Cerus: Focused on Safeguarding the Blood Supply To make the INTERCEPT® Blood System the Our Mission standard of care for transfused blood components Pathogen Inactivation/Reduction Market Leader with ~20 years in the market Our Reach Global sales in >40 countries Cumulative kit sales for > 20 millio

  5. Slide 5: Why CERS?

    Why CERS? • Market leader in pathogen reduction technologies for transfused blood components • First mover advantage and significant barriers to entry for competition • Repeat orders from longstanding and growing customer base contributes to recurring revenues • Concentrated blood banking customers

  6. Slide 6: Cerus' Current Products and Development Pipeline

    Cerus’ Current Products and Development Pipeline INTERCEPT Blood Systems Early Development Registration Studies Regulatory Commercially Available Commercially available in the U.S. Commercially available in Europe1 Platelets Commercially available in Latin America2 Joint venture with Shandong Zhongb

  7. Slide 7: Large & Growing Global Addressable Market Opportunity for INTERCEPT

    Large & Growing Global Addressable Market Opportunity* for INTERCEPT Addressable Markets for $5.0B Worldwide Platelet Market Commercially Available INTERCEPT Products $1.3B Potential TAM Growth Today 5-7 Years $0.7B Global $1.3 B >$1.5 B U.S. $150 MM >$200 MM $202 MM to $300MM $204 MM Cerus 2025 Fib

  8. Slide 8: 2024 Product Revenue and Revised 2025 Product Revenue Guidance

    2024 Product Revenue and Revised 2025 Product Revenue Guidance* $210 $202-204* $190 $180.3 $170 $162.2 Revised 2025 product revenue $156.4 guidance range: Product Revenue ($ million) $150 $202 million to $204 million* $130.9 $130 Includes 2025 IFC∞ revenue guidance range: $110 $16 million to $17 mil

  9. Slide 9: The Unmet Need: Proactive Protection of the Blood Supply and Ensuring Availability

    The Unmet Need: Proactive Protection of the Blood Supply and Ensuring Availability Not to be Reproduced

  10. Slide 10: Why the Blood Supply?

    Why the Blood Supply? Blood Transfusion is a Common and Critical Supportive Therapy Used for Many Types of Patients >100 million units of blood are donated per year worldwide DONOR BLOOD CENTER HOSPITAL PATIENT A single donation of whole blood can be used to make four major blood components: PLATELE

  11. Slide 11: Emerging Pathogens: Is Testing a Sustainable Solution?

    Emerging Pathogens: Is Testing a Sustainable Solution? Development time, cost, continual emergence of new pathogens 30 years of testing = protection against 11 agents HIV, Hepatitis B, Hepatitis C, HTLV, bacteria, West Nile virus, T. Cruzi, Syphilis, Babesiosis, Zika, Leukocytes Zika Babesiosis Cost

  12. Slide 12: Treatment Process - INTERCEPT Blood System for Platelets and Plasma

    Treatment Process - INTERCEPT Blood System for Platelets and Plasma 2 Inactivate* INT200 UVA Illuminator* (A similar treatment set is used for platelets.) *INT200 displayed in the images. CE Mark approved in the EU. Not approved for commercial sale in the U.S. and Canada. 12 Not to be Reproduced

  13. Slide 13: INTERCEPT Blood System for Platelets & Plasma Pathogen Reduction System

    INTERCEPT® Blood System for Platelets & Plasma Pathogen Reduction System INTERCEPT crosslinks DNA and RNA Enveloped viruses to prevent pathogen replication Non-enveloped Potential Pathogens INTERCEPT viruses in Donated Platelet Platelet component Gram-negative Donor Patient bacteria Gram-positive ba

  14. Slide 14: INT200 - Next Generation LED Based Illumination Device

    INT200 - Next Generation LED Based Illumination Device • Intuitive Design, Simplified Handling • Touch Screen Navigation, Intuitive Software • Improved Tray Design • Intelligent Scanning • Custom Reporting • Compact Design • Streamlined for a Faster Workflow • Select regulatory approvals to date • C

  15. Slide 15: Be Ready. When Minutes Matter

    Be Ready. When Minutes Matter ® Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex, IFC) produced from the Not to be Reproduced INTERCEPT® Blood System for Cryoprecipitation MKT-EN 00472-02, v9.0 *INTERCEPT Fibrinogen Complex is available for immediate use for up to

  16. Slide 16: Hemorrhage is a Leading Cause of Preventable Death

    Hemorrhage is a Leading Cause of Preventable Death1 #1 ~40% 1.6 Cause Hours Trauma is the #1 cause of death Of these, ~40% are The median time to death from in adults <45 years old2 the result of bleeding2 exsanguination* is 1.6 hours3,4 Trauma5,6 Cardiac (CV) Surgery7 Postpartum Hemorrhage8 Combat9

  17. Slide 17: What is INTERCEPT Fibrinogen Complex (IFC)?

    What is INTERCEPT® Fibrinogen Complex (IFC)? • INTERCEPT® Fibrinogen Complex is a pathogen reduced blood component for fibrinogen supplementation • Approved to treat and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency • Immediate*, enriched source of key fact

  18. Slide 18: Shorter Turnaround Times (TAT) & Minimized Wastage

    Shorter Turnaround Times (TAT) & Minimized Wastage IFC accelerates availability, minimizes wait times and increases reliability and predictability of blood component delivery. Barnes-Jewish 1 C 2 3 Hospital 4 40 min 10 min Order to Issue IFC reduces blood component wastage, improving blood stewardsh

  19. Slide 19: The cost of thawing cryo AHF

    The cost of thawing cryo AHF OR Costs of Cryo  If a patient is in the OR, bleeding and needs AHF Wait Time fibrinogen, waiting an additional 24 minutes to thaw cryo AHF costs approximately $1,200 $1200  ($50 per minute X 24 minutes)  This estimate does not include the costs of the additional bloo

  20. Slide 20: INTERCEPT Red Blood Cells Development Program

    INTERCEPT Red Blood Cells Development Program* * INTERCEPT Red Blood Cells are in development and are not currently licensed for sale in any geography. Not to be Reproduced

  21. Slide 21: INTERCEPT RBC Clinical Development Program

    INTERCEPT RBC Clinical Development Program1 Successfully Completed Ongoing In Vitro Characterization Recovery & Lifespan In Vitro Characterization Recovery and Survival (Grifols Sets)(n=65) (n=26) (Grifols Sets) (Fenwal Sets)(n=65) (Fenwal Sets)(n=24) Report in Progress Completed Report in Progress

  22. Slide 22: Q3:25 Financial Results and Highlights

    Q3:25 Financial Results and Highlights 22 Not to be Reproduced

  23. Slide 23: Focus on Execution, Coupled with Commitment Fueling Sustainable Growth

    Focus on Execution, Coupled with Commitment Fueling Sustainable Growth ✓ U.S. INTERCEPT Platelet adoption continues to increase Hospital IFC demand growing Germany evaluating additional steps to reduce TTI Enrollment in U.S. Phase 3 RedeS trial completed European regulatory review of INTERCEPT RBC c

  24. Slide 24: Third Quarter Results Reflect Ongoing Sales Momentum

    Third Quarter Results Reflect Ongoing Sales Momentum Quarterly Product Revenue Product Revenue $55.0 • Q3:25 product revenue of $52.7 million, +15% year-over-year (Y/Y) $50.0 • North American product revenue growth $45.0 of 11% Y/Y millions • EMEA reported product revenue growth of $40.0 21% Y/Y; no

  25. Slide 25: Sixth Consecutive Quarter of Positive Non-GAAP Adjusted EBITDA

    Sixth Consecutive Quarter of Positive Non-GAAP Adjusted EBITDA‡ UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA $ millions Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 YTD ‘25 Net Loss Attributable to Cerus Corporation (9.7) (5.8) (2.9) (2.5) (7.7) (5.7) - (13.4) Adjustments to Net Loss Attributab

  26. Slide 26: Quarterly Cash and Operating Cash Flow Trends

    Quarterly Cash* and Operating Cash Flow Trends $100.0 $20.0 $15.0 $90.0 $10.0 $80.0 $5.0 Cash flow from operations Cash, cash equivalents, & $70.0 $- ($ Millions) short-term investments ($ Millions) $(5.0) $60.0 $(10.0) $50.0 $(15.0) $40.0 $(20.0) Q1:23 Q2:23 Q3:23 Q4:23 Q1:24 Q2:24 Q3:24 Q4:24 Q1:2

  27. Slide 27: Where Do We Go From Here?

    Where Do We Go From Here? Future Expansion of INTERCEPT’s Global Reach INTERCEPT Blood System for Platelets & Plasma Extend leadership Anticipated expansion into Development of next- in current markets new markets (e.g., China) generation products INTERCEPT Fibrinogen Complex Penetration across the

  28. Slide 28: Cerus Corporation

    Cerus Corporation Investor Relations IR@cerus.com (925) 288-6137 Not to be Reproduced

Cerus — Investor Presentation (December 2025) on 6ix